-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation